@InvestingVisual With platforms like IB and RobinHood there is already a 24h/5 trading session (even if with tiny volumes). So would this change move the needle?
@Raul_DSF We are on the same boat mate, just I took a more conservative $40m FCF, which is still huuuuge for their EV.
My main concern is the balance sheet (1st risk in micro caps). Perhaps the acquisition of Spotlight had a bad timing, but I'm trusting management here
@Raul_DSF Did they guide (or hint) for $50m FCF in 2026? Seems a lot to me to assume a 20% growth next year with the new Google algo's update in December 2025...
Today I added to $FOUR at $62.5, $LFMD at $4.95 and $HIMS at $39.8
Sweet prices, supported by irrational moves on Four and Hims strong Q3 reports, and LifeMd sale of WorkSimpli.
$FI just dropped a disaster of a quarter.
Curious to see how $FOUR performs on Nov 6, very different stories, but still an interesting comparison.
At this point, I don’t think $FI is in any position to acquire them now with all this mess.
Today we announce a strategic investment in $GRAL — the most advanced Multi-Cancer Early Detection (MCED) test on the market.
When I was 12, my father was diagnosed with stage 4 colon cancer. He was 38 at the time, about the same age as I am today.
Since hearing about early detection cancer tests nearly 5 years ago, I’ve been obsessed with finding ways to get more people I love access. I started with my family a few years back, and most recently my friends.
With today’s announcement, I’m now focused on all of you.
The ability to detect cancer in its early stages was a dream when I was a kid. It was what I wanted more than anything after my dad was diagnosed.
What $GRAL can do today is nothing short of magic. It is flipping cancer diagnosis on its head. Imagine the ability to catch it early. No more surprises, no more “if onlys.” Just a simple, annual blood test that’s as easy as going to the dentist. For many, it could be life-changing, helping you or a family member find out early, when something can hopefully be done.
Today’s strategic investment is the first of many like it, in our pursuit to curate the absolute best in advanced healthcare.
This deal, though, is special to me, and I couldn’t be more excited to one day bring it to you and the people you love.
https://t.co/rm5ThoIvz9
Note on forward-looking statements: https://t.co/31UsHAJgkf
@kermyt_houghts Exactly.
Analysts have too much obsession with quarterly “organic growth” while missing the real story.
$FI might fit in, but their stock’s been hammered lately. I think that $120/sh is the minimum here
At $73.7, I think it’s a great time to start a position in $FOUR.
I’m genuinely impressed by their M&A playbook in fintech — it has that same disciplined, compounding mindset you see in Constellation Software $CSU.
Wouldn’t be surprised if it gets taken private around $140.
@leadership_net Yes. It is already lower than 1 year ago. Probably margins will be structurally a bit lower, but that's not that important for the price we are paying!
$GAMB looks extremely attractive at these levels — solid mix of M&A, cash flow, and organic growth.
Risks are there (mainly Google algorithm dep), but the valuation already prices them in. Management seems smartly focused on diversifying away from that risk.
Underrated setup.
$GAMB looks extremely attractive at these levels — solid mix of M&A, cash flow, and organic growth.
Risks are there (mainly Google algorithm dep), but the valuation already prices them in. Management seems smartly focused on diversifying away from that risk.
Underrated setup.
$BABA keeps pushing higher 🚀 after CEO Eddie Wu’s AI/AGI/ASI vision + big AI capex.
Market cap: $400B
Net cash: $50B 💰
Segments: e-commerce (domestic + intl), cloud, AI & other bets.
Strategic company for China🇨🇳
Still looks cheap vs potential!